ATE488581T1 - Faktor vii oder faktor viia polypeptidvarianten - Google Patents

Faktor vii oder faktor viia polypeptidvarianten

Info

Publication number
ATE488581T1
ATE488581T1 AT03717173T AT03717173T ATE488581T1 AT E488581 T1 ATE488581 T1 AT E488581T1 AT 03717173 T AT03717173 T AT 03717173T AT 03717173 T AT03717173 T AT 03717173T AT E488581 T1 ATE488581 T1 AT E488581T1
Authority
AT
Austria
Prior art keywords
factor
polypeptide variants
variants
viia polypeptide
vii
Prior art date
Application number
AT03717173T
Other languages
English (en)
Inventor
Jesper Haaning
Kim Andersen
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of ATE488581T1 publication Critical patent/ATE488581T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03717173T 2002-04-30 2003-04-29 Faktor vii oder faktor viia polypeptidvarianten ATE488581T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37667902P 2002-04-30 2002-04-30
PCT/DK2003/000276 WO2003093465A1 (en) 2002-04-30 2003-04-29 FACTOR VII OR VIIa POLYPEPTIDE VARIANTS

Publications (1)

Publication Number Publication Date
ATE488581T1 true ATE488581T1 (de) 2010-12-15

Family

ID=29401388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03717173T ATE488581T1 (de) 2002-04-30 2003-04-29 Faktor vii oder faktor viia polypeptidvarianten

Country Status (22)

Country Link
US (6) US7700733B2 (de)
EP (1) EP1499719B1 (de)
JP (2) JP2005523723A (de)
KR (1) KR101121593B1 (de)
CN (2) CN101942019A (de)
AT (1) ATE488581T1 (de)
AU (2) AU2003221469A1 (de)
BR (1) BR0309576A (de)
CA (1) CA2483478A1 (de)
CY (1) CY1111626T1 (de)
DE (1) DE60334983D1 (de)
DK (1) DK1499719T3 (de)
ES (1) ES2355713T3 (de)
IL (1) IL164764A (de)
MX (1) MXPA04010781A (de)
NZ (1) NZ536340A (de)
PL (1) PL373728A1 (de)
PT (1) PT1499719E (de)
RU (1) RU2004134726A (de)
SI (1) SI1499719T1 (de)
WO (1) WO2003093465A1 (de)
ZA (1) ZA200409475B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1982732A3 (de) 2000-02-11 2011-06-08 Bayer HealthCare LLC Faktor VII- oder VIIA-ähnliche Konjugate
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7700733B2 (en) * 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
EP1549677B1 (de) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG
DK2085470T3 (da) 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
DK1644504T3 (da) 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
EP2392655A3 (de) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Gerinnungsfaktor VII Polypeptide
CN106916802B (zh) 2003-12-01 2022-03-25 诺和诺德医疗保健公司 液体因子vii组合物的病毒过滤
KR20150138427A (ko) 2003-12-19 2015-12-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
BRPI0514396A2 (pt) 2004-08-17 2009-05-12 Csl Behring Gmbh polipeptìdeos dependentes de vitamina k modificada
AU2005282065B2 (en) * 2004-09-10 2013-02-07 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
JP2008525381A (ja) 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
US20080188400A1 (en) * 2005-04-26 2008-08-07 Maxygen Holdings Ltd. Methods For Treating Bleeding
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US7696318B2 (en) 2005-07-13 2010-04-13 Novo Nordisk Health Care Ag Host cell protein knock-out cells for production of therapeutic proteins
EP1924689B1 (de) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Reinigung von faktor-vii-polypeptiden mittels hydrophober interaktionschromatografie
WO2007031559A2 (en) 2005-09-14 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
EP2031968B1 (de) * 2006-04-21 2017-11-22 Wake Forest University Health Sciences Strukturell modifizierte azelluläre gewebe-engineering-gerüste und herstellungsverfahren
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
EP2114379A2 (de) * 2006-12-20 2009-11-11 Bayer HealthCare LLC Faktor-vi- und -viia-zusammensetzungen
EP2481797A1 (de) * 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen dafür
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
CN101918025A (zh) 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
CA2747825A1 (en) 2009-01-22 2010-07-29 Novo Nordisk Health Care Ag Stable growth hormone compounds
EP2461831B1 (de) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Wachstumshormone mit verlängerter in-vivo-wirksamkeit
WO2011018515A1 (en) 2009-08-14 2011-02-17 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
CN106913874A (zh) * 2010-02-22 2017-07-04 优势医疗公司 治疗脑的出血性病状的方法和组合物
WO2012138854A1 (en) 2011-04-05 2012-10-11 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2554161A1 (de) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmazeutische Zusammensetzung enthaltend Faktor VII in Mizellen verkapselt
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
WO2013177584A2 (en) * 2012-05-25 2013-11-28 The Children's Hospital Of Philadelphia FVIIa VARIANTS EXHIBITING ALTERED INTERACTION WITH ENDOTHELIAL PROTEIN C RECEPTOR (EPCR) AND METHODS OF USE THEREOF FOR MODULATING HEMOSTASIS
KR102047235B1 (ko) * 2012-12-24 2019-11-22 바이엘 헬스케어 엘엘씨 단작용성 인자 vii 폴리펩티드
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
FI882746L (fi) 1987-06-12 1988-12-13 Hoechst Japan Hybridprotein c och foerfarande foer dess framstaellning.
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
JP2928287B2 (ja) * 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69101634T4 (de) 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
JP3330932B2 (ja) 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
EP0785273A1 (de) 1990-11-26 1997-07-23 Genetics Institute, Inc. Gepaarte basische Aminosäuren konvertierendes Enzym und dafür kodierende DNA Sequenz
WO1992015686A1 (en) 1991-02-28 1992-09-17 Zymogenetics, Inc. Modified factor vii
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
GB9122048D0 (en) * 1991-10-17 1991-11-27 Interox Chemicals Ltd Compositions and uses thereof
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
AU703110B2 (en) 1993-05-21 1999-03-18 Novo Nordisk A/S Modified factor VII
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE365210T1 (de) 1998-10-30 2007-07-15 Novozymes As Glykosylierte proteine mit reduzierter allergenität
JP2003500003A (ja) 1998-10-30 2003-01-07 ノボザイムス アクティーゼルスカブ 低いアレルゲン性のタンパク質変異型
ATE408020T1 (de) 1998-11-06 2008-09-15 Novo Nordisk Healthcare Ag Verfahren zur herstellung von faktor vii
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
EP1982732A3 (de) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Faktor VII- oder VIIA-ähnliche Konjugate
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
HUP0301246A3 (en) 2000-09-13 2005-12-28 Novo Nordisk Healthcare Ag Human coagulation factor vii variants
RU2326126C2 (ru) * 2000-09-13 2008-06-10 Ново Нордиск Хелт Кэр Аг Полипептид фактора vii свертывания крови, его получение и применение
EP1325127B1 (de) * 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Verfahren zur herstellung vitamin-k-abhängiger proteine
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
IL157842A0 (en) 2001-03-22 2004-03-28 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
US7052868B2 (en) * 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
ATE532858T1 (de) 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag Menschliche gerinnungsfaktor-vii-polypeptide
ES2490590T3 (es) 2001-11-02 2014-09-04 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación humana
US7024693B2 (en) * 2001-11-13 2006-04-04 Sun Microsystems, Inc. Filter-based attribute value access control
RU2357751C2 (ru) 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
US7700733B2 (en) * 2002-04-30 2010-04-20 Bayer Healthcare Llc Factor VII or VIIa polypeptide variants
EP1549677B1 (de) 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG
DK2085470T3 (da) * 2003-03-20 2012-08-06 Bayer Healthcare Llc FVII- eller FVIIa-varianter
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
US7185570B2 (en) 2005-01-18 2007-03-06 Chih-Ching Hsieh Spanner with enhancing structure for positioning electronic devices installed therein
US20060252669A1 (en) 2005-05-06 2006-11-09 Marija Heibel Fabric care composition comprising polymer encapsulated fabric or skin beneficiating ingredient

Also Published As

Publication number Publication date
WO2003093465A1 (en) 2003-11-13
PL373728A1 (en) 2005-09-05
ES2355713T3 (es) 2011-03-30
MXPA04010781A (es) 2005-03-07
DE60334983D1 (de) 2010-12-30
IL164764A0 (en) 2005-12-18
IL164764A (en) 2013-07-31
ZA200409475B (en) 2005-09-28
KR101121593B1 (ko) 2012-04-12
JP2010213706A (ja) 2010-09-30
CY1111626T1 (el) 2015-10-07
US20060270002A1 (en) 2006-11-30
CA2483478A1 (en) 2003-11-13
US20100260741A1 (en) 2010-10-14
EP1499719A1 (de) 2005-01-26
SI1499719T1 (sl) 2011-03-31
AU2003221469A1 (en) 2003-11-17
BR0309576A (pt) 2005-02-09
US9353365B2 (en) 2016-05-31
US20060270000A1 (en) 2006-11-30
NZ536340A (en) 2006-09-29
AU2008261165A1 (en) 2009-01-15
CN1665925A (zh) 2005-09-07
PT1499719E (pt) 2011-02-09
US7700733B2 (en) 2010-04-20
US20060276377A1 (en) 2006-12-07
KR20040106424A (ko) 2004-12-17
JP2005523723A (ja) 2005-08-11
DK1499719T3 (da) 2011-02-28
CN101942019A (zh) 2011-01-12
US20060270001A1 (en) 2006-11-30
US20060111282A1 (en) 2006-05-25
EP1499719B1 (de) 2010-11-17
RU2004134726A (ru) 2005-06-10

Similar Documents

Publication Publication Date Title
DE60334983D1 (de) Faktor vii oder faktor viia polypeptidvarianten
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
DK1257295T3 (da) Faktor VII eller VIIA-lignende molekyler
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
DE69809558D1 (de) Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2
ATE295829T1 (de) Verwendung von biologisch aktivem glas zum schneiden von biologisch aktivem glas
PL370536A1 (en) Compositions for treatment of common cold
DK2085470T3 (da) FVII- eller FVIIa-varianter
DK1107996T3 (da) Humane anti-faktor IX/IXa-antistoffer
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
ATE389013T1 (de) Faktor x-analoge mit verbesserter fähigkeit zur aktivierung
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
HUP0400458A2 (hu) Kobalaminkötő fehérjéket expresszáló transzgenikus növények
DE60222669D1 (de) Asthma-assoziiertes gen
IN2009CN00831A (de)
FR2830865B1 (fr) Leurres peptidiques pour la preparation de medicaments destines a la prevention ou au traitement des pathologies auto-immunes, ou des troubles lies a l'apparition d'anticorps diriges contre des proteines exogenes
EP1490388A4 (de) Neue zusammensetzungen und verfahren bei krebs, der mit einer veränderten exprimierung von kcnj9 assoziiert ist
BR0211522A (pt) Tratamento de dor crÈnica com 3-arilóxi-3-fenilpropanaminas
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
DE60129133D1 (de) Verwendung von Clarithromycin zur Herstellung eines Medikaments für die Behandlung von Arthrosis deformans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1499719

Country of ref document: EP